CJC-1295 DAC Protocol: Complete Cycling & Dosing Guide

Overview

CJC-1295 DAC is a long-acting synthetic growth hormone-releasing hormone (GHRH) analogue designed to stimulate sustained endogenous growth hormone secretion. The Drug Affinity Complex (DAC) modification binds the peptide to serum albumin, creating a depot effect that extends its active half-life to 6–8 days—a dramatic increase from the minutes-long duration of native GHRH.

This extended pharmacokinetic profile makes CJC-1295 DAC fundamentally different from unmodified CJC-1295 (which requires 2–3 times weekly dosing). The once-weekly injection schedule, combined with its mechanism of stimulating endogenous GH release rather than replacing it exogenously, positions CJC-1295 DAC as a popular choice in anti-aging protocols, body composition optimization, and athletic recovery contexts.

Critical Transparency Note: CJC-1295 DAC has not been studied in humans for efficacy in muscle growth, hormonal balance, or any other therapeutic outcome. The only published human study is an analytical chemistry paper on urine metabolite detection for anti-doping purposes—it provides zero evidence of biological effect or clinical safety. The information below is based on mechanistic understanding, pharmacokinetics, and practical protocol experience in research and user communities, not clinical trial data. It is educational content only.

Standard Protocol

Dosing Framework

Standard Maintenance Dose: 1000–2000 mcg (1–2 mg) injected once weekly

• Lower end (1 mg/week): Suitable for initial users, individuals sensitive to peptides, those over 50, or those seeking conservative GH axis stimulation
• Mid-range (1.5 mg/week): The most common effective dose across protocols; balances tissue-building drive with tolerability
• Upper end (2 mg/week): Reserved for experienced users, younger athletes, or those with prior exposure to GHRH peptides

Cycle Structure

On-Cycle Duration: 12–24 weeks is standard

• 12-week cycles: Appropriate for first-time users or those testing tolerance; sufficient to assess effect trajectory
• 16-week cycles: The modal protocol; allows full tissue remodeling while minimizing desensitization risk
• 24-week cycles: Used in extended anti-aging or body composition protocols; requires monitoring for receptor tolerance

Rest Periods: 4–8 weeks between cycles

• After a 12-week cycle: 4 weeks off minimum
• After a 16-week cycle: 6 weeks off
• After a 24-week cycle: 8 weeks off

The rest period allows GH axis receptors and signaling to reset, preventing tachyphylaxis (diminishing response over time).

Dose Escalation

Most users employ a conservative titration approach:

• Week 1–2: Start at 1000 mcg once weekly; assess tolerance and response
• Week 3–4: If tolerated well, escalate to 1500 mcg once weekly
• Week 5+: Advance to 2000 mcg once weekly if further response is desired and side effects remain minimal

This approach identifies individual sensitivity before committing to higher doses and allows the body to acclimatize to GH axis upregulation.

Goal-Specific Protocols

Protocol A: Body Composition & Lipolysis (12-week cycle)

Primary Goal: Fat loss with preservation or modest lean mass gain

Dosing:

• Weeks 1–2: 1000 mcg once weekly
• Weeks 3–12: 1500 mcg once weekly

Timing: Inject on the same day each week (e.g., Monday morning)

Nutrition: Maintain a mild caloric deficit (300–500 kcal/day below maintenance); adequate protein (1.0–1.2 g/lb bodyweight)

Training: 3–4 days/week resistance training + 2–3 days/week low-intensity steady-state cardio (walking, cycling)

Rest Period: 6 weeks off before next cycle

Protocol B: Lean Mass Accumulation & Strength (16-week cycle)

Primary Goal: Muscle gain with minimal fat addition

Dosing:

• Weeks 1–2: 1000 mcg once weekly
• Weeks 3–8: 1500 mcg once weekly
• Weeks 9–16: 2000 mcg once weekly

Timing: Inject same day each week; some protocols inject in the evening to align GH pulse with sleep

Nutrition: Slight caloric surplus (200–400 kcal/day above maintenance); high protein intake (1.2–1.4 g/lb bodyweight)

Training: 4–5 days/week progressive resistance training; compound movements prioritized

Supplementation: Creatine monohydrate (5 g/day), essential amino acids or whey protein post-training

Rest Period: 6–8 weeks off

Protocol C: Recovery & Anti-Aging (20-week cycle)

Primary Goal: Tissue repair, skin quality, joint health, sustained GH signaling

Dosing:

• Weeks 1–20: 1000–1500 mcg once weekly (steady dose; no escalation)

Timing: Inject same day each week; evening injection preferred to enhance nocturnal GH secretion

Lifestyle: Emphasis on sleep (8+ hours/night), stress management, daily movement

Supplementation: Collagen peptides (10–20 g/day), hyaluronic acid, antioxidants; some add low-dose NAD+ precursors

Training: Moderate intensity; mix of resistance and mobility work

Rest Period: 8 weeks off; longer rest period to allow complete axis recovery

How to Administer: Step-by-Step

Preparation (Before Every Injection)

1. Verify the Compound: Confirm the label indicates CJC-1295 DAC with a clear expiration date; all legitimate vendors provide batch/lot numbers
2. Inspect the Vial: Check for particulates, discoloration, or cloudiness; a clear, colorless to slightly off-white lyophilized powder is normal
3. Gather Materials: Sterile syringe (insulin or TB syringe, typically 0.5 mL), sterile needle (27 or 30 gauge), sterile bacteriostatic water or normal saline for reconstitution, alcohol swabs, sharps container

Reconstitution (First Use Only)

1. Calculate Water Volume: For a standard 2 mg vial:

   • Add 2 mL bacteriostatic water to achieve 1000 mcg/mL concentration
   • Alternatively, add 1 mL water for 2000 mcg/mL (more concentrated, smaller injection volume)

2. Draw Sterile Water: Using a fresh syringe and needle, draw the prescribed volume of bacteriostatic water

3. Inject into Vial: Slowly inject the water into the CJC-1295 DAC vial at an angle; do not spray directly onto the powder

4. Let Sit: Allow 2–3 minutes for the powder to fully dissolve; do not shake vigorously (can denature peptide); gentle swirling is acceptable

5. Verify Clarity: The solution should be clear and colorless; if cloudiness persists, discard and obtain a fresh vial

6. Label: Mark the vial with the date of reconstitution and an expiration date (typically 20–30 days if stored properly)

Weekly Injection Procedure

1. Calculate Dose: Determine the volume needed based on concentration:

   • If 1000 mcg/mL and dose is 1500 mcg, draw 1.5 mL
   • If 2000 mcg/mL and dose is 1500 mcg, draw 0.75 mL

2. Sanitize Vial Top: Swab the rubber septum of the reconstituted vial with an alcohol wipe; let dry 10 seconds

3. Draw into Syringe: Using a fresh sterile needle, draw the calculated volume into the syringe; expel any air bubbles

4. Select Injection Site: Typical sites are:

   • Subcutaneous (preferred): Belly fat, love handles, back of upper arm, or thigh (less painful, easier administration)
   • Intramuscular: Gluteus maximus, vastus lateralis, or deltoid (deeper penetration, slightly different pharmacokinetics)
   • Most users prefer subcutaneous injection for convenience

5. Prepare Skin: Swab the injection site with an alcohol wipe; wait 10 seconds for alcohol to dry

6. Inject: Pinch or spread skin slightly; insert needle at 45–90 degrees; inject slowly to minimize pressure and discomfort; withdraw needle and apply light pressure with gauze for 5–10 seconds

7. Dispose: Immediately place used needle and syringe into a sharps container; do not recap

Storage

• Unreconstituted Vial: Store at 2–8°C (refrigerator); stable for 2–3 years if unopened
• Reconstituted Solution: Store at 2–8°C; stable for 20–30 days with bacteriostatic water as diluent; do not freeze
• During Travel: Use an insulated cooler with ice packs; keep temperature between 2–8°C

Cycle Example: Week-by-Week Schedule (16-Week Lean Mass Protocol)

Injection Timing: Administer every Monday at the same time (e.g., 7 AM); consistency improves steady-state pharmacokinetics

Training Progression: Weeks 1–4 establish baseline and acclimate to higher GH; Weeks 5–12 where most measurable lean mass gains occur; Weeks 13–16 consolidation and minor strength peaks

What to Expect: Timeline of Effects

First 24–48 Hours Post-Injection

• Possible transient fatigue or warmth at injection site
• Mild flushing or warmth sensation across face/neck (typically subsides within 1–2 hours)
• Early water retention begins; some users notice a "tighter" feeling in connective tissue

Week 1–2

• Noticeable increase in water retention; scale weight may increase 2–4 lbs from fluid
• Improved sleep quality (often the first noticeable effect)
• Mild headache (resolves within 24 hours post-injection in most users)
• Baseline hunger and appetite increase

Week 3–6

• Water retention stabilizes
• Gradual increase in appetite and food intake
• Improved skin quality (slight increase in hydration and firmness)
• Strength gains begin to accumulate; users report improved recovery between training sessions
• Joint/tendon sensation often improves (reduced stiffness, especially upon waking)

Week 7–12

• Noticeable body composition shift if diet and training are aligned
• In hypertrophic protocols: measurable lean mass gain (typically 2–4 lbs of actual muscle over 8 weeks)
• In fat loss protocols: accelerated lipolysis; users often report easier appetite control
• Improved exercise capacity; ability to tolerate higher training volume
• Hair and nail growth may accelerate

Week 13–16

• Continued gradual progress; response may plateau slightly (normal and expected)
• Cumulative improvements in body composition become visually apparent
• Possible receptor downregulation beginning; this is why longer rest periods are implemented
• Residual water retention typically remains until 2–3 weeks post-cycle

Post-Cycle (Weeks 17–24)

• Gradual decline in water retention; scale weight normalizes over 3–4 weeks
• GH/IGF-1 levels decline; recovery speed may slow
• Appetite normalizes
• Lean mass gains are retained; this is not a loss of muscle but normalization of fluid

Common Protocol Mistakes

Mistake 1: Injecting Every Day or Multiple Times Per Week

CJC-1295 DAC's 6–8 day half-life means daily or twice-weekly dosing leads to excessive accumulation and side effects (extreme water retention, headaches, elevated IGF-1). Stick to once weekly.

Mistake 2: Exceeding 2 mg Per Week

Doses above 2 mg/week offer diminishing returns and increase side effect risk without proportional benefit. The GHRH receptor has a saturation point.

Mistake 3: Running Excessively Long Cycles Without Rest

Cycles beyond 24 weeks dramatically increase tachyphylaxis (receptor desensitization) risk. The GH axis requires downtime to remain responsive. Implement mandatory rest periods.

Mistake 4: Inadequate Nutrition

CJC-1295 DAC dramatically increases appetite and GH signaling, but without sufficient calories and protein, it cannot drive tissue remodeling. Align nutrition with your goal (surplus for mass, deficit for fat loss).

Mistake 5: Poor Injection Technique or Site Rotation

Repeated injections in the same location cause lipohypertrophy and uneven absorption. Rotate injection sites systematically (e.g., left abdomen Week 1, right abdomen Week 2, left thigh Week 3, etc.).

Mistake 6: Ignoring Water Retention Management

Water retention is normal but manageable. Maintain consistent sodium intake (do not restrict excessively), ensure adequate potassium (from food), and prioritize sleep. Excessive water retention may indicate too-high dosing.

Mistake 7: Reconstitution Without Bacteriostatic Water

Reconstituting with non-sterile or non-bacteriostatic water risks contamination and peptide degradation. Always use pharmaceutical-grade bacteriostatic water or preservative-free normal saline.

How to Stack with Other Compounds

Stack 1: CJC-1295 DAC + GHRP-6 (Synergistic GH Release)

Rationale: GHRP-6 is a GH secretagogue that activates a distinct receptor pathway, creating synergistic GH stimulation when combined with the GHRH pathway activation of CJC-1295 DAC

Protocol:

• CJC-1295 DAC: 1500 mcg once weekly (Monday morning)
• GHRP-6: 100–200 mcg injected 3 times daily (morning, midday, evening), typically before meals

Consideration: This significantly increases injection frequency and water retention; reserve for experienced users or those with specific hypertrophy goals

Stack 2: CJC-1295 DAC + Testosterone Replacement (Anabolic Synergy)

Rationale: Exogenous testosterone amplifies GH-driven anabolism; GH enhances androgen receptor sensitivity

Protocol:

• CJC-1295 DAC: 1500–2000 mcg once weekly
• Testosterone: 100–200 mg/week IM (if using TRT replacement doses) or per individual protocol

Consideration: Requires monitoring of hematocrit, lipid panel, and prostate health; suitable only for those already using or prescribed testosterone

Stack 3: CJC-1295 DAC + Thyroid Hormone (Recovery Acceleration)

Rationale: CJC-1295 DAC stimulates GH; thyroid hormone (T4 or combined T4/T3) upregulates metabolic rate and tissue turnover

Protocol:

• CJC-1295 DAC: 1000–1500 mcg once weekly
• Levothyroxine: 25–50 mcg daily (if replacing or supplementing T4; dose depends on baseline thyroid function)

Consideration: Requires baseline TSH testing; use only under informed protocols; hyperthyroidism risk if dosed incorrectly

Stack 4: CJC-1295 DAC + Insulin-Like Growth Factor-1 (IGF-1 Amplification)

Rationale: CJC-1295 DAC stimulates endogenous IGF-1; exogenous IGF-1 provides additional localized growth signaling

Protocol:

• CJC-1295 DAC: 1500 mcg once weekly
• IGF-1 LR3 or IGF-1 Des: 40–100